A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants
22 de janeiro de 2019 atualizado por: Janssen Research & Development, LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants
The purpose of this study is to evaluate safety and tolerability of JNJ-64991524 compared with placebo after administration of single ascending oral doses of JNJ-64991524 (Part 1) and multiple ascending oral doses of JNJ-64991524 (Part 2) in healthy participants.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
- Medicamento: JNJ-64991524 Dose Level 1
- Medicamento: Placebo
- Medicamento: JNJ-64991524 Dose Level 2
- Medicamento: JNJ-64991524 Dose Level 3
- Medicamento: JNJ-64991524 Dose Level 4
- Medicamento: JNJ-64991524 Dose Level 5
- Medicamento: JNJ-64991524 Dose Level 6
- Medicamento: JNJ-64991524 Dose Level 7
- Medicamento: JNJ-64991524 Dose Level 8
- Medicamento: JNJ-64991524 Dose Level 9
Tipo de estudo
Intervencional
Inscrição (Real)
86
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Antwerpen, Bélgica, 2060
- SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 60 anos (Adulto)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Weigh at least 50 kilogram (kg), and have a body mass index (BMI) of 18 kg/ meter (m)^2 to 30 kg/m^2, inclusive, at screening
- Be otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead ECG performed at screening and Day-1. This determination must be recorded in the participant's source documents and initialed by the investigator
- Be otherwise healthy on the basis of clinical laboratory tests performed at screening and Day -1. If the results of the serum chemistry panel, including liver enzymes, white blood cell count and hematocrit, coagulation, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and confirmed initialed by the investigator
- Have the platelet count pretreatment clinical laboratory values not below the normal range during Screening and Day -1
- A woman must have a negative serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test on Day -2
Exclusion Criteria:
- History of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-64991524 or its excipients
- History of severe allergic reaction, angioedema, or anaphylaxis to drugs or food
- Has a history of malignancy before screening. Exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or a malignancy which is considered cured with minimal risk of recurrence
- Has a history of or is infected with human immunodeficiency virus (HIV [positive serology for HIV antibody]); tests positive for hepatitis B virus (HBV) infection; has antibodies to hepatitis C virus (HCV) at screening
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)
Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
|
|
Experimental: Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
|
|
Experimental: Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
|
|
Experimental: Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)
Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
|
|
Experimental: Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
|
|
Experimental: Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)
Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
|
|
Experimental: Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
|
|
Experimental: Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
|
|
Experimental: Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
|
|
Experimental: Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)
Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
|
Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Part 1: Single Ascending Dose (SAD): Number of Participants with Treatment Emergent Adverse Events (AEs) as a Measure of Safety and Tolerability
Prazo: Up to Day 20
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Treatment-emergent were events between administration of study drug and up to Day 20 that were absent before treatment or that worsened relative to pre-treatment state.
|
Up to Day 20
|
|
Part 2: Multiple Ascending Dose (MAD): Number of Participants with Treatment Emergent Adverse Events as a Measure of Safety and Tolerability
Prazo: Up to Day 28
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Treatment-emergent were events between administration of study drug and up to Day 28 that were absent before treatment or that worsened relative to pre-treatment state.
|
Up to Day 28
|
|
Number of Participants with Abnormalities in Vital Signs, Physical Examinations, Electrocardiogram (ECG), Cardiac Telemetry and Clinically Significant Laboratory Findings
Prazo: Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Number of participants with abnormalities in vital signs, physical examinations, ECG, cardiac telemetry and clinically significant laboratory findings will be measured.
|
Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Plasma Concentration of JNJ-64991524
Prazo: Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Plasma concentration assessment will be done to characterize the pharmacokinetics (PK) of JNJ-64991524.
|
Pre-dose, up to Day 20 (SAD) and up to Day 28 (MAD)
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
15 de novembro de 2017
Conclusão Primária (Real)
20 de novembro de 2018
Conclusão do estudo (Real)
20 de novembro de 2018
Datas de inscrição no estudo
Enviado pela primeira vez
15 de novembro de 2017
Enviado pela primeira vez que atendeu aos critérios de CQ
15 de novembro de 2017
Primeira postagem (Real)
17 de novembro de 2017
Atualizações de registro de estudo
Última Atualização Postada (Real)
24 de janeiro de 2019
Última atualização enviada que atendeu aos critérios de controle de qualidade
22 de janeiro de 2019
Última verificação
1 de janeiro de 2019
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- CR108376
- 2017-000229-11 (Número EudraCT)
- 64991524EDI1001 (Outro identificador: Janssen Research & Development, LLC)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em JNJ-64991524 Dose Level 1
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Janssen, LPConcluídoDengueEstados Unidos
-
Janssen Research & Development, LLCConcluídoObesidade e Diabetes Mellitus tipo 2Estados Unidos
-
Janssen Research & Development, LLCConcluído
-
Janssen Research & Development, LLCConcluídoObesidadeEstados Unidos, Bélgica, Reino Unido, Suécia, Polônia, Canadá
-
Janssen Research & Development, LLCRetirado
-
Janssen Research & Development, LLCConcluído
-
Janssen Research & Development, LLCConcluído
-
Aplagon OyLINK Medical Research AB; Estimates OYRecrutamentoDoença Arterial Oclusiva Periférica | Isquemia Crônica Ameaçadora de MembrosFinlândia
-
Janssen Research & Development, LLCConcluído
-
University Rovira i VirgiliUniversity of Valladolid; Sanidad de Castilla y LeónDesconhecidoQueimaduras | Papel da enfermeira | Lesão Térmica